| Overview |
| bsm-51238M |
| AKT1 (6C1) Monoclonal Antibody |
| WB |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| This AKT1 Monoclonal antibody is generated from mouses immunized with a KLH conjugated synthetic peptide selected from the 430-460 region of human AKT1. |
| Monoclonal |
| 6C1 |
| IgG1 |
| 0.5ug/ul |
| Mouse monoclonal antibody supplied in crude ascites with 0.09% (W/V) sodium azide. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C for 12 months. |
| Target |
| 207 |
| P31749 |
| AKT; PKB; RAC; CWS6; PRKBA; PKB-ALPHA; RAC-ALPHA; RAC-alpha serine/threonine-protein kinase; Protein kinase B; Protein kinase B alpha; PKB alpha; Proto-oncogene c-Akt; RAC-PK-alpha; AKT1 |
| The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Mutations in this gene have been associated with the Proteus syndrome. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2011] |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz